METIS TECHBIO-P Shares Surge Over 11% on Launch of AiProtein Platform and AARON Antibody Design Agent

Stock News05-27

METIS TECHBIO-P (07666) saw its shares rise more than 11% during the trading session. As of the time of writing, the stock was up 6.96% to HK$17.51, with a turnover of HK$63.37 million. The catalyst for the move was the company's official launch of its AiProtein platform and the antibody design agent AARON. As the fourth core solution driven by METIS TECHBIO-P's AI nano-delivery platform NanoForge, AiProtein, together with AiLNP, AiRNA, and AiTEM, completes the company's end-to-end "Rocket + Satellite" R&D loop encompassing protein design, mRNA sequence design, and LNP design. Notably, on May 18, METIS TECHBIO-P announced a strategic collaboration with GRIT Biotechnology on immunotargeted LNP technology, signing a comprehensive strategic agreement. This partnership is not a simple technology outsourcing arrangement but represents a deep integration between two technology-driven biotech firms in the cutting-edge field of in vivo immunotherapy. METIS TECHBIO-P will leverage its globally first AI nano-delivery platform, NanoForge, to help GRIT Biotechnology overcome delivery bottlenecks for its next-generation cell therapy drugs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156492942?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156492942","market":"nz","top_or_hot":-1,"title":"METIS TECHBIO-P Shares Surge Over 11% on Launch of AiProtein Platform and AARON Antibody Design Agent","media":"Stock News","content":"<p>METIS TECHBIO-P (07666) saw its shares rise more than 11% during the trading session. As of the time of writing, the stock was up 6.96% to HK$17.51, with a turnover of HK$63.37 million. The catalyst for the move was the company's official launch of its AiProtein platform and the antibody design agent AARON. As the fourth core solution driven by METIS TECHBIO-P's AI nano-delivery platform NanoForge, AiProtein, together with AiLNP, AiRNA, and AiTEM, completes the company's end-to-end \"Rocket + Satellite\" R&D loop encompassing protein design, mRNA sequence design, and LNP design. Notably, on May 18, METIS TECHBIO-P announced a strategic collaboration with GRIT Biotechnology on immunotargeted LNP technology, signing a comprehensive strategic agreement. This partnership is not a simple technology outsourcing arrangement but represents a deep integration between two technology-driven biotech firms in the cutting-edge field of in vivo immunotherapy. METIS TECHBIO-P will leverage its globally first AI nano-delivery platform, NanoForge, to help GRIT Biotechnology overcome delivery bottlenecks for its next-generation cell therapy drugs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>METIS TECHBIO-P Shares Surge Over 11% on Launch of AiProtein Platform and AARON Antibody Design Agent</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMETIS TECHBIO-P Shares Surge Over 11% on Launch of AiProtein Platform and AARON Antibody Design Agent\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-27 14:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>METIS TECHBIO-P (07666) saw its shares rise more than 11% during the trading session. As of the time of writing, the stock was up 6.96% to HK$17.51, with a turnover of HK$63.37 million. The catalyst for the move was the company's official launch of its AiProtein platform and the antibody design agent AARON. As the fourth core solution driven by METIS TECHBIO-P's AI nano-delivery platform NanoForge, AiProtein, together with AiLNP, AiRNA, and AiTEM, completes the company's end-to-end \"Rocket + Satellite\" R&D loop encompassing protein design, mRNA sequence design, and LNP design. Notably, on May 18, METIS TECHBIO-P announced a strategic collaboration with GRIT Biotechnology on immunotargeted LNP technology, signing a comprehensive strategic agreement. This partnership is not a simple technology outsourcing arrangement but represents a deep integration between two technology-driven biotech firms in the cutting-edge field of in vivo immunotherapy. METIS TECHBIO-P will leverage its globally first AI nano-delivery platform, NanoForge, to help GRIT Biotechnology overcome delivery bottlenecks for its next-generation cell therapy drugs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1156492942","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156492942","pubTimestamp":1779863541,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"METIS TECHBIO-P (07666) saw its shares rise more than 11% during the trading session. As of the time of writing, the stock was up 6.96% to HK$17.51, with a turnover of HK$63.37 million. The catalyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","07666":"剂泰科技-P","BK4588":"碎股"},"translate_title":"METIS TECHBIO-P推出AiProtein平台和AARON抗体设计代理后股价飙升超过11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07666":1,"VXUS":1},"content_text":"METIS TECHBIO-P (07666) saw its shares rise more than 11% during the trading session. As of the time of writing, the stock was up 6.96% to HK$17.51, with a turnover of HK$63.37 million. The catalyst for the move was the company's official launch of its AiProtein platform and the antibody design agent AARON. As the fourth core solution driven by METIS TECHBIO-P's AI nano-delivery platform NanoForge, AiProtein, together with AiLNP, AiRNA, and AiTEM, completes the company's end-to-end \"Rocket + Satellite\" R&D loop encompassing protein design, mRNA sequence design, and LNP design. Notably, on May 18, METIS TECHBIO-P announced a strategic collaboration with GRIT Biotechnology on immunotargeted LNP technology, signing a comprehensive strategic agreement. This partnership is not a simple technology outsourcing arrangement but represents a deep integration between two technology-driven biotech firms in the cutting-edge field of in vivo immunotherapy. METIS TECHBIO-P will leverage its globally first AI nano-delivery platform, NanoForge, to help GRIT Biotechnology overcome delivery bottlenecks for its next-generation cell therapy drugs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156492942","isCrawlerRequest":true}